PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 EUR | 0.00% | +1.20% | -35.87% |
Sales 2024 * | 1.05M 1.12M | Sales 2025 * | 1.6M 1.71M | Capitalization | 17.92M 19.16M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 1M 1.07M | EV / Sales 2024 * | 17.5 x |
Net Debt 2024 * | 450K 481K | Net Debt 2025 * | 10.55M 11.28M | EV / Sales 2025 * | 17.8 x |
P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-3.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
Latest transcript on PHAXIAM Therapeutics S.A.
1 week | +1.03% | ||
Current month | -1.01% | ||
1 month | +1.72% | ||
3 months | -28.05% | ||
6 months | -33.41% | ||
Current year | -35.87% |
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.95 | 0.00% | 16,261 |
24-04-25 | 2.95 | +1.20% | 941 |
24-04-24 | 2.915 | -0.17% | 1,540 |
24-04-23 | 2.92 | -0.68% | 1,047 |
24-04-22 | 2.94 | +0.68% | 731 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock